정문교 (삼성바이오로직스)님 | 한빛사연구자 > 한빛사

삼성바이오로직스

최종업데이트 2024.09.12.

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment
- Adv. Mater., Sep 10 2024, | https://doi.org/10.1002/adma.202410340
- 2024-09
- 바이오·의료융합
- 한빛사논문
A personalized cancer nanovaccine that enhances T-cell responses and efficacy through dual interactions with dendritic cells and T cells
- Adv. Mater., 2023 Jul 29;e2303979 | https://doi.org/10.1002/adma.202303979
- 2023-07
- 바이오·의료융합
- 한빛사논문
Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment
- Nano Lett., 2023 Jan 13 | https://doi.org/10.1021/acs.nanolett.2c03682
- 2023-01
- 바이오·의료융합
- 한빛사논문
A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer’s disease
- Adv. Mater., First published: 03 November 2022 | https://doi.org/10.1002/adma.202207719
- 2022-11
- 바이오·의료융합
- 한빛사논문
Nanovesicle-mediated targeted delivery of immune checkpoint blockades to potentiate therapeutic efficacy and prevent side effects
- Adv. Mater., First published: 28 December 2021 | https://doi.org/10.1002/adma.202106516
- 2021-12
- 바이오·의료융합
- 한빛사논문

연구자 ID

저자논문